Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
Cidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
12:41pm, Tuesday, 09'th Sep 2025
Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:00 AM EDT Company Participants Ryuk Byun - Managing Director Jeffrey Stein - Presid
Cidara Therapeutics to Participate in September Investor Conferences
08:00am, Thursday, 04'th Sep 2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeut
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting
08:00am, Wednesday, 03'rd Sep 2025
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeu
Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout
01:07pm, Friday, 15'th Aug 2025
Cidara Therapeutics, Inc.'s CD388's strong phase 2b results significantly de-risk CDTX and highlight its potential as a superior flu prophylactic, especially for high-risk patients. Multiple short-ter
Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript
06:04pm, Friday, 08'th Aug 2025
Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Frank L. Karbe - Chief Financial Officer Jeffrey L.
Cidara (CDTX) Q2 Cash Surges 163%
04:37pm, Thursday, 07'th Aug 2025
Cidara (CDTX) Q2 Cash Surges 163%
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025
08:00am, Thursday, 24'th Jul 2025
SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunother
Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics
01:00pm, Monday, 07'th Jul 2025
MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #AntiviralTreatment--Segal Trials proudly announces its participation in the successful Phase 2b NAVIGATE clinical trial conducted by Cidara Therapeutics, evaluati
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:59pm, Tuesday, 01'st Jul 2025
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therap
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
02:21pm, Monday, 30'th Jun 2025
The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
08:00am, Monday, 30'th Jun 2025
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therap
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
05:15pm, Thursday, 26'th Jun 2025
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (
Cidara Therapeutics Advances CD388 To Phase 3, Reiterate Buy
07:30am, Wednesday, 25'th Jun 2025
Cidara Therapeutics' main value driver, CD388, recently achieved an impressive 76% protection in its Phase 2b trials. It also showed a compelling safety profile. In my view, CD388 now has a clear path
Cidara Announces Pricing of Upsized Public Offering of Common Stock
08:00pm, Tuesday, 24'th Jun 2025
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (
Cidara Announces Proposed Public Offering of Common Stock
04:15pm, Monday, 23'rd Jun 2025
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (
